Upstream Bio (NASDAQ:UPB) Research Coverage Started at William Blair

William Blair started coverage on shares of Upstream Bio (NASDAQ:UPB) in a research report report published on Tuesday, MarketBeat Ratings reports. The firm issued an outperform rating on the stock. William Blair also issued estimates for Upstream Bio’s Q4 2024 earnings at ($0.42) EPS, FY2025 earnings at ($2.36) EPS, FY2026 earnings at ($2.64) EPS, FY2027 earnings at ($2.15) EPS and FY2028 earnings at ($2.26) EPS.

Separately, TD Cowen assumed coverage on Upstream Bio in a research report on Tuesday. They set a “buy” rating for the company.

Upstream Bio Trading Up 1.7 %

UPB stock opened at $27.02 on Tuesday. Upstream Bio has a 1-year low of $20.74 and a 1-year high of $29.46.

Insider Activity

In other Upstream Bio news, Director Erez Chimovits bought 825,000 shares of the stock in a transaction on Tuesday, October 15th. The shares were acquired at an average price of $17.00 per share, with a total value of $14,025,000.00. Following the acquisition, the director now directly owns 4,554,873 shares of the company’s stock, valued at $77,432,841. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Upstream Bio news, major shareholder Ai Upstream Llc acquired 1,175,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The shares were bought at an average price of $17.00 per share, for a total transaction of $19,975,000.00. Following the completion of the transaction, the insider now owns 1,175,000 shares of the company’s stock, valued at approximately $19,975,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Erez Chimovits acquired 825,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 15th. The shares were acquired at an average cost of $17.00 per share, with a total value of $14,025,000.00. Following the purchase, the director now directly owns 4,554,873 shares of the company’s stock, valued at $77,432,841. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.